Atrium Therapeutics, Inc.
NASDAQ:RNABiotechnology
+$0.16 today
- Market cap
- $143.23M
- Beta
- 0.42
- P/E (TTM)
- -3.3
- EPS (TTM)
- -$3.78
Volume 0.22M
Average 0.35M
RNA Operating Cash Flow
Cash generated by the company's core business operations during the period.
Atrium Therapeutics, Inc.NASDAQ: RNA
Operating Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Operating cash flow of -$31.14M in Q1 FY2026
Q1 FY2026 operating cash flow was -$31.14M.
Context
- Operating cash flow amounted to 220.9% of revenue in FY2025.
Sources:Cash FlowText generated from reported figures; not investment advice.
Operating Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (41.13M) USD
- Year-over-year change
- —
| Period | Period end | Operating Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (41.13M) | — |
Operating Cash Flow vs competitors
How RNA compares with its peers on the latest reported figures
No competitor Operating Cash Flow figures are available to compare.
Cash Flow Statement
Atrium Therapeutics, Inc.
NASDAQ:RNA
Intrinsic Alpha fair value
Locked
Current Price
$6.64
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.